Affidea acquires Q Diagnostica and enters the Spanish market
Affidea Group, a European leader in diagnostic imaging and cancer treatment services, announces that, after receiving all necessary legal approvals, it has successfully completed the acquisition of 100% of the shares in Q Diagnostica from Alantra Private Equity. Affidea thus enters the Spanish market and strengthens its position in Europe.
Founded in 1989, Q Diagnostica is the leading private provider of medical services in Spain, focused on diagnostic imaging technologies, with 33 centers and 3 mobile units in 7 Spanish regions. Q Diagnostica is equipped with Magnetic Resonance Imaging (MRI), Computerized Axial Tomography (CAT), Positron Emission Tomography (PET) among many other diagnostic systems and employs 430 professionals - 120 of them radiologists - performing more than 400,000 tests per year.
Dimitris Moulavasilis, CEO of Affidea Group, commented on the acquisition: "Adding Q Diagnostica to the Affidea network and entering the Spanish market is a testament to our commitment to staying the course, offering a unique value proposition and further expanding the quality healthcare offering to patients across Europe. Q Diagnostica is a business with great growth potential and a superb professional reputation in Spain. We look forward to tackling the next stage of its development together. I am pleased to welcome Q Diagnostica colleagues into our Affidea team and we look forward to a seamless integration that will benefit our patients, our staff and the entire healthcare system. This is what the success of our company is based on."
With the acquisition of Q Diagnostica, Affidea Group expands its network to 212 cancer diagnostic and treatment centers in 16 countries across Europe, with a focus on providing rapid and comprehensive diagnostics along with the highest quality treatments, based on the use of cutting-edge technology and experienced medical professionals. Affidea Group employs nearly 4,000 healthcare professionals, including 800 physicians.
Q Diagnostica will initially operate under the same name and Iñaki Eguía will continue to serve as CEO in Spain, providing leadership to better serve the needs of Spanish patients, the medical community, the National Health System, private health insurers and other partners.
Iñaki Eguía, CEO of Q Diagnostica, said, "Joining the European leader in diagnostic imaging and cancer treatment services, both in number of centers and quality, is an important milestone for Q Diagnostica. Spain is a competitive market and patients continue to demand better medical care, but we are confident about the future, we are convinced that combining medical excellence with state-of-the-art medical infrastructure and know-how is the perfect recipe for Q Diagnostica to continue on the path to success."
About Affidea Group
Affidea is a leading European healthcare investment group through Private Public Partnerships (PPP). The company provides diagnostic radiology, clinical laboratory and cancer treatment services in more than 212 wholly owned medical centers in 16 countries: Poland, Hungary, Romania, Bosnia, Croatia, Greece, Italy, Turkey, Czech Republic, Ireland, Switzerland, Lithuania, Bulgaria, Portugal, Spain and Serbia.
For the latest Affidea news, visit https://affidea.es/es/.